Chairman Kang Il-mo Increases Stake in KM Pharmaceutical by 0.26% Through Open Market Purchases, Ownership Rises to 37.90%

Chairman Kang Il-mo, a non-registered executive and major shareholder of KM Pharmaceutical, purchased a total of 14,421 shares on the open market on June 29 and July 1, 2026.
The purchase price ranged from 1,706 to 1,775 won per share, averaging 1,732 won, which is approximately 6.3% below the current market price of 1,848 won.
This increased his ownership from 37.64% to 37.90%, a modest 0.26 percentage point gain. The small scale of the purchase limits its impact on share price or governance.
No dilutive securities such as convertible bonds or warrants are reported, and no capital changes or additional financing plans are disclosed.
[AI Summary]This disclosure shows a minor insider buying by the largest shareholder, which may signal confidence but lacks material impact on shareholder value. No dilution risk or governance shifts are present; the transaction is best viewed as a routine personal investment decision.